• Product NameCrenolanib
• Brief DescriptionInhibitors
• Purification99.28%
• Biological ActivityCrenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.
• Target NamePDGFR inhibitor
• CAS No. 670220-88-9
• Calculated MW 443.54
• Formulation C26H29N5O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1(COC2=CC3=C(C=C2)N(C=N3)C2=NC3=C(C=CC=C3N3CCC(N)CC3)C=C2)COC1
  Pathways:Angiogenesis
  Receptor:PDGFRα; PDGFRβ
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 7 mg/mL (15.78 mM); DMSO: 89 mg/mL warmed (200.65 mM)
  Appearance:Faint Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Heinrich MC, et al, Clin Y Res, 2012, Jun 27.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting